Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 176

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 176
---
 31, 2024, and 2023

During the second quarter of 2023, the Company decided to streamline its operations by terminating clinic services and suspending non-lead R&D projects. This measure is aimed at optimizing the allocation of our resources and focusing our efforts on advancing our lead projects, which hold the most promise for commercial success and beneficial impact. This decision aligns with our commitment to enhance shareholder value and effectively drive our core objectives forward in the competitive landscape.

<div align='center'>86</div>

The following table summarizes
our results of operations for the years ended December 31, 2024, and 2023.

|                                                                          |     | Year Ended   
 December 31, 
 2024         |            |   |     | Year Ended   
 December 31, 
 2023         |             |   |
|:-------------------------------------------------------------------------|:----|:-------------|-----------:|:--|:----|:-------------|------------:|:--|
| Revenue                                                                  |     |              |            |   |     |              |             |   |
| Healthcare services income                                               |     | $            |          - |   |     | $            |     431,378 |   |
| Operating expenses                                                       |     |              |            |   |     |              |             |   |
| Cost of healthcare services                                              |     |              |          - |   |     |              |    (420,812 | ) |
| Research and development expenses                                        |     |              | (2,195,161 | ) |     |              |  (5,198,329 | ) |
| General and administrative fees                                          |     |              |   (669,486 | ) |     |              |  (1,930,637 | ) |
| Legal and professional fees                                              |     |              |   (803,285 | ) |     |              |  (2,538,161 | ) |
| Other operating expenses                                                 |     |              |   (272,609 | ) |     |              |  (1,067,690 | ) |
| Total expenses                                                           |     |              | (3,940,541 | ) |     |              | (11,155,629 | ) |
| Other (expense) income, net                                              |     |              |            |   |     |              |             |   |
| Loss on investments in marketable securities, net                        |     |              |          - |   |